The $178.7M Moderna settlement payment expected in July 2026 transforms the balance sheet — cash will rise to ~$274M, or ~$1.39/share. Watch for capital return plans (management flagged evaluation in Q3 2026). The FDA Fast Track for imdusiran is a positive regulatory catalyst, but the stock's re-rating depends on execution of the Pfizer/BioNTech LNP litigation, which remains unresolved.
Price Chart
Executive Summary
Arbutus reported Q1 2026 GAAP net income of $169.7M ($0.87 diluted EPS), a massive swing from a $24.5M loss in Q1 2025, driven by $178.7M in license revenue from Genevant related to the Moderna settlement. Excluding this one-time item, core operating expenses fell sharply to $10.2M from $27.5M, reflecting prior restructuring. The stock will move on the visibility of the $178.7M cash receipt in July 2026 and the FDA Fast Track designation for imdusiran, but the underlying business remains a pre-revenue clinical-stage biotech.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $179.1M vs $1.8M YoY, driven by $178.7M license revenue from Genevant/Moderna settlement
- GAAP net income $169.7M ($0.87 diluted EPS) vs net loss $24.5M ($-0.13) YoY
- Cash and marketable securities $95.2M at March 31, 2026, up from $91.5M at Dec 31, 2025
- Company expects to receive ~$178.7M from Moderna settlement in July 2026
- FDA granted Fast Track designation for imdusiran (chronic hepatitis B) in April 2026
- R&D expenses fell to $4.1M from $9.0M YoY; no restructuring costs vs $12.4M in Q1 2025
- Operating cash burn $8.1M in Q1 2026, improved from $13.4M in Q1 2025
- 196.9M shares outstanding as of March 31, 2026
Financial Impact
Q1 2026 net income of $169.7M vs consensus loss of $0.06 EPS; revenue of $179.1M vs $1.5M consensus. The $178.7M license receivable from Genevant is a one-time event, but adds ~$0.91 per share to book value.
Risk Factors
- Core business is pre-revenue — ongoing operating cash burn of ~$8M/quarter
- Pfizer/BioNTech LNP litigation outcome uncertain; no settlement timeline
- Contingent $1.3B Moderna payment depends on appellate ruling on Section 1498
- Imdusiran still in Phase 2a; no guarantee of regulatory approval or commercial success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003346 |
| Document: f8k_051226.htm | 0001171843-26-003346 |
| Document: 0001171843-26-003346-index-headers.html | 0001171843-26-003346 |
| Document: 0001171843-26-003346-index.html | 0001171843-26-003346 |
| Document: 0001171843-26-003346.txt | 0001171843-26-003346 |
| 8-K Data (Synthetic) | 0001171843-26-003346 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | 8-K | $5.21 $5.00 | ▼ −4.03% | ▼ −3.50% | $4.45 (−14.59%) |
Aug 15, 2026 6w ago | Institutional Cluster | $4.71 $5.06 | ▲ +7.43% | ▲ +9.41% | $4.45 (−5.52%) |
Aug 12, 2026 7w ago | 8-K | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Aug 12, 2026 7w ago | Press Release | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Jul 16, 2026 11w ago | 8-K | $4.74 $4.58 | ▼ −3.38% | ▼ −6.99% | $4.45 (−6.12%) |
Jun 12, 2026 16w ago | Institutional Cluster | $4.26 $4.80 | ▲ +12.68% | ▲ +10.90% | $4.45 (+4.46%) |
May 13, 2026 20w ago | 8-K | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
May 13, 2026 20w ago | Press Release | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
Apr 15, 2026 24w ago | 8-K | $4.48 $4.31 | ▼ −3.79% | ▼ −9.84% | $4.45 (−0.67%) |
Mar 23, 2026 27w ago | Press Release | $4.42 $4.43 | ▲ +0.23% | ▼ −7.19% | $4.45 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access